At a major medical conference in Rio de Janeiro, researchers presented new options to prevent and treat HIV. For a long time, patients had to take daily pills. Now, scientists developed new choices that people do not need to take every day.
One new option is an injection that protects against HIV for six months. Another choice is a weekly pill for people who already live with HIV. These options are very effective, and they help patients follow their treatment routines. Some African countries, such as Zambia and Zimbabwe, are already using the new injection.
However, bringing these medicines to everyone is still difficult. Recent cuts in global funding disrupted healthcare delivery in many nations. Governments are now working to make the new treatments affordable and available in local clinics.
Difficult words
- conference — a large meeting where people discuss important topics
- researcher — a person who studies something to find new informationresearchers
- injection — putting a medicine into the body using a needle
- effective — producing a good result or working very well
- affordable — cheap enough for ordinary people to buy or pay for
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why do you think long-acting injections or weekly pills are easier for patients than daily pills?
- What can governments do to help local clinics get important new medicines?
Related articles
Older adults more exposed to low-credibility online health information
Researchers at the University of Utah tracked web activity of more than 1,000 US adults for four weeks. They found low-credibility health sites were rare overall but visits were concentrated among older adults, especially those who lean right politically.
Gut has a backup system for IgA antibodies
Researchers found two different routes that make IgA antibodies in the gut. Early IgA often comes from non‑germinal center cells but later from germinal centers; both types showed similar specificity and mutations, which may help vaccine design.